Trial Profile
A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Carboplatin; Paclitaxel; Pegfilgrastim
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 30 Mar 2017 Status changed from active, no longer recruiting to completed.
- 09 Mar 2017 Results (n=14) of two dose expansion cohorts, published in the Investigational New Drugs
- 04 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.